Integrative Medicine Research (IMR) is a quarterly, peer-reviewed, subsidized open access journal focused on scientific research in integrative medicine including traditional medicine, complementary and alternative medicine, and systems medicine. The journal aims to provide new research perspectives on integrative health of the whole person, and to yield points of convergence for medical and bioscience circles. The journal includes papers on scientific research; clinical research; topical review; computational analysis and modeling; education and policy; wellbeing; lifestyle intervention; and systems approaches in integrative medicine. IMR is the official journal of Korea Institute of Oriental Medicine.
Manuscripts for Integrative Medicine Research may be submitted via EVISE Editorial System (https://www.evise.com/evise/jrnl/IMR). For editorial questions, please contact us via email at firstname.lastname@example.org, telephone (+82 42 868 9392), or fax (+82 42 869 2720).
- Articles should be prepared in the simplest form possible and submitted in Microsoft Word (*.doc or *.docx). Manuscripts must be typed in English, double-spaced and 10 or 12-point type. And all pages must be numbered consecutively starting from the title page.
- You may use automatic page numbering, but do NOT use other kinds of automatic formatting such as footnotes.
- Put text, references, tables, and legends in one file, with each table on a new page.
- Authors are required to be in compliance with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, which are compiled by the International Committee of Medical Journal Editors (ICMJE), available at www.icmje.org.
(1) A cover letter. It must include your name, address, telephone and fax numbers, e-mail address, and state that all authors have contributed to the paper and have never submitted the manuscript, in whole or in part, to other journals.
(2) A conflict of interest disclosure statement (see relevant section below).
(3) Articles covering the use of human samples in research and human experiments must be approved by the relevant review committee (see relevant section below).
(4) Articles covering the use of animals in experiments must be approved by the relevant authorities.
(5) Articles where human subjects can be identified in descriptions, photographs or pedigrees must be accompanied by a signed statement of informed consent to publish (in print and online) the descriptions, photographs and pedigrees from each subject who can be identified (see relevant section below).
(6) Clinical trials are recommended to register a primary national clinical trial registration site such as http://www.clinicaltrials.gov, http://ncrc.cdc.go.kr/cris, or other sites accredited by WHO or the International Committee of Medical Journal Editors.
(7) Where material has been reproduced from other copyrighted sources, the letter(s) of permission from the copyright holder(s) to use the copyrighted sources must be supplied.
(8) Articles should be written in English (using American English spelling) and meet the following basic criteria: the material is original, the information is important, the writing is clear, concise and grammatically correct, the study methods are appropriate, the data are valid, and the conclusions are reasonable and supported by the data. For non-native English-speaking authors, we suggest that manuscripts be checked and edited by a native English speaker.
Editorials are invited articles or comments concerning a specific paper in the Journal or a topical issue in the field. Although editorials are normally invited or written by an Editor, unsolicited editorials may be submitted.Typical length: 1,500-2,000 words, 20-40 references.
These should aim to provide the reader with a balanced overview of an important and topical subject related to basic research, clinical research, methodology, theory, computational analysis and modelling, topical reviews, medical history, education and policy based on physiology, pathology, diagnosis and the systems approach in the field of integrative medicine. Most reviews are solicited by the editors, but unsolicited submissions may also be considered for publication. Section headings should be: Abstract, Introduction, brief main headings, and References. Typical length: 2,000-4,000 words, 50-100 references.
These may be randomized trials, intervention studies, studies of screening and diagnostic tests, laboratory and animal studies, cohort studies, cost-effectiveness analyses, case-control studies, surveys with high response rates, and historical, social, or policy studies on integrative medicine and health, which represent new and significant contributions to the field. Section headings should be: Abstract, Introduction, Methods, Results, Discussion, Acknowledgments (if applicable), References.
The Introduction should provide a brief background to the subject of the paper, explain the importance of the study, and state a precise study question or purpose. The Methods section should describe the study design and methods (including the study setting and dates, patient samples or animal specimens used, with inclusion and exclusion criteria, the laboratory methods followed, or data sources and how these were selected for the study, the essential features of any interventions, the main outcome measures), and state the statistical procedures employed in the research.The Results section should comprise the study results presented in a logical sequence, supplemented with tables and/or figures. Take care that the text does not repeat data that are presented in the tables and/or figures.
The Discussion section should be used to emphasize the new and important aspects of the study, placing the results in context with published literature, the implications of the findings, and the conclusions that follow from the study results. Typical length: 2,000-3,000 words, no limitation on the number of reference.
These are short discussions of a case or case series with unique features not previously described that make an important teaching point or scientific observation. Section headings should be: Abstract, Introduction, Case Report, Discussion, Acknowledgments (if applicable), References. The Introduction should describe the purpose of the report, the significance of the disease and its specificity, and briefly review the relevant literature.
The Discussion should compare, analyze and discuss the similarities and differences between the reported case and similar previously reported cases. The importance or specificity of the case should be restated when discussing the differential diagnoses. Suggest the prognosis of the disease and possibility of prevention. Typical length: 800-1,200 words, 15-30 references.Letters to the Editor
These include brief constructive comments concerning previously published articles in the journal. Letters should have a title and include appropriate references, and include the corresponding author's e-mail address. Letters are edited, sometimes extensively, to sharpen their focus. They may be sent for peer review at the discretion of the Editors. Typical length: 300-600 words, 5 references; 1 table and/or 1 figure may be included.
These are short, opinion articles which focus on current research topics and highlight articles of interest previously published elsewhere. Commentaries should have a title, a summary of a focal article, a comment/critique, a conflict of interest statement, and appropriate references. The summary may be subdivided into sections to better describe a focal article: aim, design, setting, participants, intervention, main outcome measures, main results, and author's conclusion. Commentaries are generally invited by the Editors, but interested contributors with unsolicited commentaries are encouraged to submit them. Typical length: 1,000-1,500 words, no more than 10 references.
These describe detailed plans for conducting clinical studies, including the purpose and methodology of the study. Study protocols should have Abstract, Background, Methods, Discussion, Conflicts of Interest, Acknowledgments (if applicable), and References.
The Methods section should describe the study design, procedures, population, treatments, assessments, follow-up, timetable, safety consideration, quality assurance, data management, statistical analysis, and ethics.The Discussion section should include important aspects, expected outcomes, problems anticipated, and limitations.
Typical length: 2,000-3,000 words, no limitation on the number of reference.
These are short reports of significant research. Short communications may include up to 2 figures or tables. Section headings should be: Abstract, Introduction, Methods, Results, Discussion, Acknowledgments (if applicable), and References.
Typical length: no more than 2,000 words, 10-30 references.
If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans; Uniform Requirements for manuscripts submitted to Biomedical journals. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.
All animal experiments should comply with the ARRIVE guidelines and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed.Submission declaration and verification
Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see 'Multiple, redundant or concurrent publication' section of our ethics policy for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service CrossCheck.
All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.
Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.
Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.
Published manuscripts become the permanent property of Korea Institute of Oriental Medicine, and must not be published elsewhere without written permission. All articles published in the Journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article, as well as translation rights. No part of this publication may be reproduced, stored in any retrieval system, or transmitted in any form or by any means, electronic, mechanical, by photocopying, recording, or otherwise, without prior written permission from Korea Institute of Oriental Medicine. A copyright transfer form should be downloaded in the Editorial System upon submission and submitted to the editorial office through the EVISE
Every peer-reviewed article appearing in this journal will be published open access. This means that the article is universally and freely accessible via the internet in perpetuity, in an easily readable format immediately after publication. The author does not have any publication charges for open access. Korea Institute of Oriental Medicine will pay to make the article open access.
A CC user license manages the reuse of the article (see http://www.elsevier.com/openaccesslicenses). All articles will be published under the following license:
Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND): for non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.
Role of the funding source
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.
The corresponding author must inform the editor of any potential conflicts of interest that could influence the author’s interpretation of the data. Examples of potential conflicts of interest are financial support from or connections to pharmaceutical companies, political pressure from interest groups, and academically related issues. Conflict of interest statements will be published at the end of the text of the article, before the ‘References’ section. Please consult the COPE guidelines (http://www.publicationethics.org/) on conflict of interest. Even when there is no conflict of interest, it should also be stated. Submission
Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.
The title page should include: category of paper, article title,names (spelled out in full) of all authors, academic degrees, the institutions with which they are affi liated (only 1 affi liation per author is permitted); indicate all affi liations with a superscripted lowercase number after the author’s name and in front of the appropriate affi liation, short running title not exceeding 30 characters, separate word count for abstract and text, and the corresponding author details (name, address, phone and fax, e-mail information).
An abstract and 3-5 relevant keywords (in alphabetical order) are required for the following article categories: Review Article, Original Article, and Case Report. Abstracts should be no more than 250 words in length. Abstracts for Original Articles and Short Communications should be structured, with the section headings: Background, Methods, Results and Conclusion. Abstracts for Review Articles and Case Reports should be unstructured in one single paragraph. But for Case Reports, it should include the significance and purpose of the case presentation, the diagnostic methods of the case, the key data, and brief comments and suggestions with regard to the case. Abstract for Study Protocols should be structured: Background, Methods, and Discussion. For selecting keywords, refer to the Index Medicus Medical Subject Headings (National Library of Medicine (US). MeSH [Internet]. Bethesda (MD): National Library of Medicine (US); 1954 [updated 2009, cited 2009 Nov 1]. Available from: http://www.nlm.nih.gov/mesh/MBrowser.html.
The text for Original Articles, for example, should include the following sections: Introduction, Methods, Results, and Discussion. The Introduction should be as concise as possible, without subheadings. The Methods section should be suffi ciently detailed. Subheadings may be used to organize the Results and Discussion. Each section should begin on a new page.
Where a term/defi nition is continually referred to (i.e. . 3 times in the text), it is written in full when it fi rst appears, followed by the subsequent abbreviation in parentheses (even if it was previously defi ned in the abstract); thereafter, the abbreviation is used.
Current standard international nomenclature for genes should be adhered to. Genes should be typed in italic font and include the accession number. For human genes, use genetic notation and symbols approved by the HUGO Gene Nomenclature Committee (http://www.genenames.org/) or refer to PubMed (http://www.ncbi.nlm.nih.gov/sites/entrez).
Systeme International (SI) units must be used, with the exception of blood pressure values which are to be reported in mmHg. Please use the metric system for the expression of length, area, mass, and volume.
Authors are responsible for the accuracy and completeness of their references and for correct text citation.
• References should be identifi ed using superscripted numbers,in numerical order, and be placed after punctuation.
• References cited in tables or fi gure legends should be included in sequence at the point where the table or figure is first mentioned in the main text.
• Do not cite abstracts unless they are the only available reference to an important concept.
• Uncompleted work or work that has not yet been accepted for publication (i.e., “unpublished observation”, “personal communication”) should not be cited as references.
In the references list
• References should be limited to those cited in the text and listed in the order in which they appear in the text.
• References should include, in order, authors’ surnames and initials, article title, abbreviated journal name, year, volume and inclusive page numbers. The last names and initials of all the authors up to 6 should be included, but when authors number 7 or more, list the fi rst 6 authors only followed by “et al”. Abbreviations for journal names should conform to those used in MEDLINE.
• If citing a website, provide the author information, article title, website address and the date you accessed the information.
• Reference to an article that is in press must state the journal name and, if possible, the year and volume.
Examples are given below.
Bisdas T, Pichlmaier M, Wilhelmi M, Bisdas S, Haverich A, Teebken O. Effects of the ABO-mismatch between donor and recipient of cryopreserved arterial homografts. Int Angiol 2011;30:247-55.
Kaplan NM. The endothelium as prognostic factor and therapeutic target: what criteria should we apply? J Cardiovasc Pharmacol 1998;32(Suppl 3):S78-80.
Kawai H, Ishikawa T, Moroi J, Hanyu N, Sawada M, Kobayashi N, et al. Elderly patient with cerebellar malignant astrocytoma. No Shinkei Geka 2008;36:799-805. [In Japanese, English abstract]
Book with edition
Bradley EL. Medical and surgical management. 2nd ed. Philadelphia: Saunders; 1982, p. 72-95. Book with editors Letheridge S, Cannon CR, editors. Bilingual education: teaching English as a second language. New York: Praeger; 1980.
Book chapter in book with editor and edition
Greaves M, Culligan DJ. Blood and bone marrow. In: Underwood JCE, editor. General and systematic pathology. 4th ed. London: Churchill Livingstone; 2004, p. 615-72.
Wilson JG, Fraser FC, editors. Handbook of teratology, vols. 1-4. New York: Plenum Press; 1977-78.
World Health Organization. World health report 2002: reducing risk, promoting healthy life. Geneva, Switzerland: World Health Organization; 2002.
Duchin JS. Can preparedness for biological terrorism save us from pertussis? Arch Pediatr Adolesc Med 2004;158(2). Available from: http://archpedi.ama-assn.org/cgi/content/full/158/2/106. Accessed June 12, 2004.
Smeeth L, Iliffe S. Community screening for visual impairment in the elderly. Cochrane Database Syst Rev 2002(2):CD001054. Doi:10.1002/14651858.CD1001054.Item presented at a meeting but not yet published
Khuri FR, Lee JJ, Lippman SM. Isotretinoin effects on head and neck cancer recurrence and second primary tumors. In: Proceedings from the American Society of Clinical Oncology, May 31-June 3, 2003; Chicago, IL. Abstract 359.
Item presented at a meeting and published
Cionni RJ. Color perception in patients with UV- or bluelightfiltering IOLs. In: Symposium on cataract, IOL, and refractive surgery. San Diego, CA: American Society of Cataract and Refractive Surgery; 2004. Abstract 337.
Ayers AJ. Retention of resin restorations by means of enamel etching and by pins [MSD thesis]. Indianapolis: Indiana University; 1971.
American Association of Oral and Maxillofacial Surgeons. Wisdom teeth. AAOMS Website. http://www.aaoms.org/wisdom_teeth.php. Published 2008. Accessed September 25, 2010.
Eastman Kodak Company, Eastman Organic Chemicals. Catalog no. 49. Rochester, NY: Eastman Kodak; 1977, p. 2-3. Acknowledgments
General acknowledgments for consultations, statistical analysis, etc., should be listed after main body of text, before the references, including the names of the individuals involved. All financial and material support for the research and the work should be stated here clearly explicitly.
Figure legends should be submitted for all figures and should be brief and specific and placed on a separate sheet after the reference section. Figures must be in numerical order using Arabic numerals in the order of their citation in the text. Figures should be uploaded as separate fi les, not embedded in the manuscript file.
Regardless of the application used, when your electronic artwork is fi nalized, please “save as” or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
• EPS: Vector drawings. Embed the font or save the text as “graphics”.
• TIFF: Color or grayscale photographs (halftones)-use a minimum of 300 dpi.
• TIFF: Bitmapped line drawings-use a minimum of 1000 dpi.
• TIFF: Combination of bitmapped line/half-tone (color or grayscale)-use a minimum of 600 dpi.
• DOC, XLS or PPT: If your electronic artwork is created in any of these Microsoft Office applications, please supply “as is”.
Please do not:
• Supply fi les that are optimized for screen use (like GIF, BMP, PICT, WPG) as the resolution is too low;
• Supply fi les that are too low in resolution;
• Submit graphics that are disproportionately large for the content.
A detailed guide on electronic artwork is available at http://www.elsevier.com/artworkinstructions. Please note that the cost of color illustrations will be charged to the author.REVIEW AND ACTION
The Editorial and Peer Review Process
As a general rule, the receipt of a manuscript will be acknowledged within 2 weeks of submission; authors will be provided with a manuscript reference number for future correspondence. If an acknowledgment is not received in a reasonable period of time, the author should contact the Editorial Office.
Submissions are reviewed by the Editorial Office to ensure that it contains all parts. Submissions will be rejected if the author has not supplied all the material and documents as outlined in the Journal's author guidelines. Manuscripts are then reviewed by the Editors, who make an initial assessment. If the manuscript does not appear to be of sufficient merit or is not appropriate for the Journal, the manuscript will be rejected without review. All other manuscripts are sent to 2 or more expert consultants for double-blind peer review. Authors will usually be notified within 12 weeks of the initial acknowledgment of whether the manuscript is accepted for publication, rejected, or subject to revision before acceptance. However, do note that delays are sometimes unavoidable.
- Responsible for the whole journal content
- Select, appoint and manage associate editors and editorial board members
- Attract high-quality manuscripts
- Assist EiC in getting manuscripts reviewed and published
- Handle articles by subject areas
- Promote the journal Managing Editor
- Assist EiC and AEs
- Handle day-to-day paperwork
- Perform technical check on all submitted manuscripts
Advisory Editorial Board
- A group of respected scholars in the field of Traditional Medicine, Complementary and Alternative Medicine, and Systems Medicine.
- Advise on policy and scope of the journal Editorial Board
- A group of respected scholars in the field of Traditional Medicine, Complementary and Alternative Medicine, and Systems Medicine.
- Assist with peer review
- Encourage others to submit manuscripts
- Submit their own work
- Suggest ideas for special issues
Use of the Digital Object Identifier
The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the journal Physics Letters B): http://dx.doi.org/10.1016/j.physletb.2010.09.059. When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to change.
One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author or, a link will be provided in the e-mail so that authors can download the files themselves. Elsevier now provides authors with PDF proofs which can be annotated; for this you will need to download Adobe Reader version 9 (or higher) available free from http://get.adobe.com/reader. Instructions on how to annotate PDF files will accompany the proofs (also given online). The exact system requirements are given at the Adobe site: http://www.adobe.com/products/reader/tech-specs.html. If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return them to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof and scan the pages and return via e-mail. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. We will do everything possible to get your article published quickly and accurately. It is important to ensure that all corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility
Track your submitted article
Track your accepted article
You are also welcome to contact the Elsevier Support Center.